Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.

Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Pérez S, Zapata A, González-García JJ, Peña JM, Vázquez JJ, Arribas JR.

J Antimicrob Chemother. 2005 May;55(5):800-4. Epub 2005 Mar 10.

PMID:
15761071
2.

Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B.

Clin Infect Dis. 2005 Oct 15;41(8):1186-95. Epub 2005 Sep 13.

PMID:
16163639
3.

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.

Martínez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, Larrousse M, León A, de Lazzari E, Gatell JM.

Clin Infect Dis. 2004 Apr 1;38(7):1017-23. Epub 2004 Mar 15.

PMID:
15034836
4.

Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.

Antivir Ther. 2005;10(5):585-91.

PMID:
16152752
5.

Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.

De Socio GV, Bonfanti P, Ricci E, Orofino G, Madeddu G, Penco G, Gianelli E, Martinelli C, Carradori S, Quirino T, Rizzardini G; CISAI Study Group.

Biomed Pharmacother. 2008 Jan;62(1):16-20. Epub 2007 Aug 21.

PMID:
17851026
7.

Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.

Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, Esteban A, Martin-Hidalgo A.

J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):594-600.

PMID:
12902803
8.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

PMID:
18294112
9.

Lopinavir/ritonavir combination and total/HDL cholesterol ratio.

Valerio L, Fontas E, Pradier C, Lavrut T, Garraffo R, Dunais B, Cua E, Dellamonica P.

J Infect. 2005 Apr;50(3):229-35.

PMID:
15780417
10.

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.

J Antimicrob Chemother. 2008 Jan;61(1):200-5. Epub 2007 Nov 13.

PMID:
17999977
11.
12.

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.

Shafran SD, Mashinter LD, Roberts SE.

HIV Med. 2005 Nov;6(6):421-5.

13.

Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.

Calza L, Manfredi R, Farneti B, Chiodo F.

Int J Antimicrob Agents. 2003 Jul;22(1):54-9.

PMID:
12842328
14.

Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler Palacín P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA.

J Antimicrob Chemother. 2008 Jan;61(1):183-90. Epub 2007 Nov 19.

PMID:
18025025
15.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin C, Burri M, Shen Y, Rode R, Nadal D; Pediatric Infectious Disease Group of Switzerland; Swiss Mother and Child HIV Cohort Study (MoCHiV).

Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

PMID:
18382386
16.

Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.

van der Lee M, Sankatsing R, Schippers E, Vogel M, Fätkenheuer G, van der Ven A, Kroon F, Rockstroh J, Wyen C, Bäumer A, de Groot E, Koopmans P, Stroes E, Reiss P, Burger D.

Antivir Ther. 2007;12(7):1127-32.

PMID:
18018771
17.

Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.

Bongiovanni M, Bini T, Chiesa E, Cicconi P, Adorni F, Monforte d'Arminio A.

Antiviral Res. 2004 Apr;62(1):53-6.

PMID:
15026202
18.

Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.

Magenta L, Dell-Kuster S, Richter WO, Young J, Hasse B, Flepp M, Hirschel B, Vernazza P, Evison J, Cavassini M, Decosterd LA, Bucher HC, Bernasconi E; Swiss HIV Cohort Study (SHCS).

AIDS Res Hum Retroviruses. 2011 May;27(5):525-33. doi: 10.1089/aid.2010.0207. Epub 2010 Nov 22.

PMID:
20854107
19.

Differentiating hyperlipidaemia associated with antiretroviral therapy.

Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO.

AIDS. 2003 Jan 24;17(2):189-94.

PMID:
12545078
20.

A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.

Antoniou T, Park-Wyllie L, Boyle E.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1666-7. No abstract available.

PMID:
15577427

Supplemental Content

Support Center